CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 632 enrolled
Drug / intervention
IMVAMUNEbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00316602
NCT00316602Phase 2Completed
CompareCT.gov

A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis

Bavarian Nordic·interventional·Posted Apr 21, 2006·Updated Jan 9, 2019

In Brief

A Phase 2 clinical trial evaluating IMVAMUNE for Atopic Dermatitis. Completed, enrolled 632 participants across 22 sites in 2 countries.

Detailed Summary

The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesMexico, United States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 21, 2006
Enrollment StartJul 1, 2006
Primary CompletionNov 1, 2009
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.2 years ago

Interventions

IMVAMUNEbiological

Subjects receiving two subcutaneous vaccinations